Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 3/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28178056 | 0.83 | CA2 (0.44) | LMNACA2CA4HDAC4CES1 | |
| SCHEMBL2488949 | 0.79 | FFAR3 (0.31) | — | |
| SCHEMBL9228208 | 0.77 | LMNA (0.38) | LMNACA2CA4HDAC4CES1 | |
| SCHEMBL10943127 | 0.75 | LMNA (0.39) | LMNACA2CA4HDAC4CES1 | |
| SCHEMBL5558534 | 0.74 | AKR1C1 (0.47) | LMNAHDAC4CYP2D6CES1CES2 | |
| SCHEMBL28629369 | 0.72 | CYP2D6 (0.35) | CYP2D6AKR1C1 | |
| SCHEMBL7784955 | 0.71 | SIGMAR1 (0.44) | LMNACYP2D6CES1CES2TSHR | |
| SCHEMBL9487687 | 0.71 | — | — | |
| SCHEMBL18951975 | 0.70 | LMNA (0.41) | LMNACA2CA4CES1CES2 | |
| SCHEMBL10946925 | 0.70 | ALDH1A1 (0.36) | LMNACES1CES2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220746-B2 | Pyrrolidinedione substituted piperidine-phthalazones as PDE4 inhibitors | ALTANA PHARMA AG (DE) | 2007-05-22 | — | — | US | disclosed |
| EP-1537100-B1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2007-04-25 | — | — | EP | disclosed |
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | ALTANA PHARMA AG (DE) | 2006-07-27 | — | — | US | disclosed |
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | ALTANA PHARMA AG (DE) | 2006-05-04 | — | — | US | disclosed |
| EP-1556049-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-07-27 | — | — | EP | disclosed |
| EP-1542987-A1 | PIPERIDINE-N-OXIDE-DERIVATIVES | ALTANA Pharma AG (DE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1537100-A1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA Pharma AG (DE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004017974-A1 | PIPERIDINE-PYRIDAZONES AND PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018450-A1 | PIPERIDINE-N-OXIDE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
| WO-2004018457-A1 | PYRROLIDINEDIONE SUBSTITUTED PIPERIDINE-PHTHALAZONES AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166995-A1 | Piperidine-n-oxide-derivatives | PDE4A, PDE3A, PDE2A | LMNA 2629/4885CA2 1403/4885CA4 425/4885 |
| US-20060160813-A1 | Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3B | LMNA 3936/4885CA2 1119/4885CA4 168/4885 |
| US-20060094710-A1 | Piperidine-pyridazones and phthalazones as pde4 inhibitors | PDE4A, PDE4B, PDE3A | LMNA 3865/4885CA2 770/4885CA4 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.